Adding a Vaccine to Immunotherapy in Lung Cancer Will It Improve Outcomes

Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?

19:00 EST 3 Mar 2019 | Cancer Networks

Researchers studied the combination of a cellular vaccine known as HS-110 and nivolumab in an early-phase trial of patients with advanced non–small-cell lung cancer.

More From BioPortfolio on "Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?"